NZ590332A - Combination of antibody 224G11 and PF-2341066 for the treatment of cancer - Google Patents

Combination of antibody 224G11 and PF-2341066 for the treatment of cancer

Info

Publication number
NZ590332A
NZ590332A NZ590332A NZ59033209A NZ590332A NZ 590332 A NZ590332 A NZ 590332A NZ 590332 A NZ590332 A NZ 590332A NZ 59033209 A NZ59033209 A NZ 59033209A NZ 590332 A NZ590332 A NZ 590332A
Authority
NZ
New Zealand
Prior art keywords
antibody
cancer
treatment
combination
composition
Prior art date
Application number
NZ590332A
Inventor
Liliane Goetsch
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20080305387 external-priority patent/EP2143441A1/en
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of NZ590332A publication Critical patent/NZ590332A/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed is a composition comprising an antibody antagonist to c-Met and an aminoheteroaryl compound, particularly as a medicament. The present invention also comprises a pharmaceutical composition comprising said anti c-Met antibody and said aminoheteroaryl compound as combination products for simultaneous, separate or sequential use. The invention relates to the use of the composition of the invention for the treatment of cancer in a mammal.
NZ590332A 2008-07-08 2009-07-08 Combination of antibody 224G11 and PF-2341066 for the treatment of cancer NZ590332A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20080305387 EP2143441A1 (en) 2008-07-08 2008-07-08 Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
US7200809A 2009-07-08 2009-07-08
PCT/EP2009/058709 WO2010003992A1 (en) 2008-07-08 2009-07-08 Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer

Publications (1)

Publication Number Publication Date
NZ590332A true NZ590332A (en) 2012-08-31

Family

ID=46755255

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ590332A NZ590332A (en) 2008-07-08 2009-07-08 Combination of antibody 224G11 and PF-2341066 for the treatment of cancer

Country Status (1)

Country Link
NZ (1) NZ590332A (en)

Similar Documents

Publication Publication Date Title
MX2011000255A (en) Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer.
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
UA104585C2 (en) Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
MY166014A (en) Combination therapy methods for treating proliferative diseases
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
GB201118656D0 (en) New compounds
WO2014062720A3 (en) Methods of treating cancer
MX361542B (en) Morphinan compounds.
IN2012DN02018A (en)
MX2013012253A (en) Novel binder-drug conjugates (adcs) and their use.
MX2007009649A (en) Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer.
MX2009006786A (en) Compositions and methods for the treatment of infections and tumors.
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
BR112014031394A2 (en) compositions and methods for transmucosal absorption
EA201490377A1 (en) TREATMENT OF MULTIPLE SCLEROSIS BY COMBINATION OF LAKVINIMODE AND GLATIRAMER ACETATE
MX2014002171A (en) Combination treatments for hepatitis c.
EA201170753A1 (en) NALMEPHENA HYDROCHLORIDE DIHYDRATE
UA111599C2 (en) COMPOSITION OF CASPOFUNGIN
MX2009005946A (en) Combination.
MX2011006725A (en) Combination of aurora kinase inhibitors and anti-cd20 antibodies.
MX2013000694A (en) Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease.
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
EA201270747A1 (en) COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF THE RAS
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
WO2009108755A3 (en) Pharmaceutical combinations for the treatment of cancer

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 08 JUL 2016 BY ACUMASS

Effective date: 20130624

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2017 BY ACUMASS

Effective date: 20160624

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2018 BY ACUMASS

Effective date: 20170624

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2019 BY ACUMASS

Effective date: 20180626

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2020 BY ACUMASS

Effective date: 20190619

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2021 BY ACUMASS

Effective date: 20200618

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2022 BY ACUMASS

Effective date: 20210618

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2023 BY ACUMASS

Effective date: 20220620

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2024 BY ACUMASS

Effective date: 20230621